These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37133639)

  • 1. In vitro activities of omadacycline, eravacycline, cefiderocol, apramycin, and comparator antibiotics against Acinetobacter baumannii causing bloodstream infections in Greece, 2020-2021: a multicenter study.
    Galani I; Papoutsaki V; Karaiskos I; Moustakas N; Galani L; Maraki S; Mavromanolaki VE; Legga O; Fountoulis K; Platsouka ED; Giannopoulou P; Papadogeorgaki H; Damala M; Chinou E; Pasxali A; Deliolanis I; Vagiakou H; Petinaki E; Chli A; Vagdatli E; Kazila P; Papaioannou V; Kontopoulou K; Ferke AN; Moraitou E; Antoniadou A; Giamarellou H
    Eur J Clin Microbiol Infect Dis; 2023 Jul; 42(7):843-852. PubMed ID: 37133639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissemination of International Clone II
    Nafplioti K; Galani I; Angelidis E; Adamou P; Moraitou E; Giannopoulou P; Chra P; Damala M; Vogiatzakis E; Trikka-Graphakos E; Baka V; Prifti E; Antoniadou A; Souli M
    Microb Drug Resist; 2020 Jan; 26(1):9-13. PubMed ID: 31393211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of apramycin (EBL-1003) in combination with colistin, meropenem, minocycline or sulbactam against XDR/PDR Acinetobacter baumannii isolates from Greece.
    Galani I; Souli M; Katsala D; Karaiskos I; Giamarellou H; Antoniadou A
    J Antimicrob Chemother; 2024 May; 79(5):1101-1108. PubMed ID: 38501368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018-2020.
    Liu PY; Ko WC; Lee WS; Lu PL; Chen YH; Cheng SH; Lu MC; Lin CY; Wu TS; Yen MY; Wang LS; Liu CP; Shao PL; Lee YL; Shi ZY; Chen YS; Wang FD; Tseng SH; Lin CN; Chen YH; Sheng WH; Lee CM; Tang HJ; Hsueh PR
    J Microbiol Immunol Infect; 2022 Oct; 55(5):888-895. PubMed ID: 34521591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced bacterial killing with a combination of sulbactam/minocycline against dual carbapenemase-producing Acinetobacter baumannii.
    Chandran S; Manokaran Y; Vijayakumar S; Shankar BA; Bakthavatchalam YD; Dwarakanathan HT; Yesudason BL; Veeraraghavan B
    Eur J Clin Microbiol Infect Dis; 2023 May; 42(5):645-651. PubMed ID: 36905566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii.
    Seifert H; Stefanik D; Sutcliffe JA; Higgins PG
    Int J Antimicrob Agents; 2018 Jan; 51(1):62-64. PubMed ID: 28705668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
    Delgado-Valverde M; Conejo MDC; Serrano L; Fernández-Cuenca F; Pascual Á
    J Antimicrob Chemother; 2020 Jul; 75(7):1840-1849. PubMed ID: 32277821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergence and spread of a multidrug-resistant Acinetobacter baumannii clone producing both the carbapenemase OXA-23 and the 16S rRNA methylase ArmA.
    Brigante G; Migliavacca R; Bramati S; Motta E; Nucleo E; Manenti M; Migliorino G; Pagani L; Luzzaro F; Viganò FE
    J Med Microbiol; 2012 May; 61(Pt 5):653-661. PubMed ID: 22282459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predominance of international clone 2 OXA-23-producing-Acinetobacter baumannii clinical isolates in Greece, 2015: results of a nationwide study.
    Pournaras S; Dafopoulou K; Del Franco M; Zarkotou O; Dimitroulia E; Protonotariou E; Poulou A; Zarrilli R; Tsakris A;
    Int J Antimicrob Agents; 2017 Jun; 49(6):749-753. PubMed ID: 28427842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of TP-6076 against carbapenem-resistant Acinetobacter baumannii isolates collected from inpatients in Greek hospitals.
    Falagas ME; Skalidis T; Vardakas KZ; Voulgaris GL; Papanikolaou G; Legakis N;
    Int J Antimicrob Agents; 2018 Aug; 52(2):269-271. PubMed ID: 29559273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
    Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
    Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of Acinetobacter baumannii clinical isolates carrying bla(OXA-23) carbapenemase and 16S rRNA methylase armA genes in Yemen.
    Bakour S; Alsharapy SA; Touati A; Rolain JM
    Microb Drug Resist; 2014 Dec; 20(6):604-9. PubMed ID: 24901296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance.
    Galani I; Nafplioti K; Adamou P; Karaiskos I; Giamarellou H; Souli M;
    BMC Infect Dis; 2019 Feb; 19(1):167. PubMed ID: 30770727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular identification of tigecycline- and colistin-resistant carbapenemase-producing Acinetobacter baumannii from a Greek hospital from 2011 to 2013.
    Mavroidi A; Likousi S; Palla E; Katsiari M; Roussou Z; Maguina A; Platsouka ED
    J Med Microbiol; 2015 Sep; 64(9):993-997. PubMed ID: 26297501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of Aminoglycoside Resistance Due to armA methylase in Multi-drug Resistant Acinetobacter Baumannii Isolates in a University Hospital in Nepal.
    Shrestha S; Tada T; Shrestha B; Kirikae T; Ohara H; Rijal BP; Pokhrel BM; Sherchand JB
    J Nepal Health Res Counc; 2016 May; 14(33):72-76. PubMed ID: 27885285
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Flamm RK; Shortridge D; Castanheira M; Sader HS; Pfaller MA
    Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of eravacycline and cefoperazone/ sulbactam against extensively-drug resistant and pan-drug resistant Acinetobacter baumannii isolates from a tertiary hospital in Greece.
    Meletis G; Protonotariou E; Gkeka I; Kassomenaki A; Mantzana P; Tychala A; Vlachodimou N; Kourti A; Skoura L
    New Microbiol; 2022 Jul; 45(3):210-212. PubMed ID: 35920876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of the novel fluorocycline TP-6076 against carbapenem-resistant Acinetobacter baumannii.
    Seifert H; Stefanik D; Olesky M; Higgins PG
    Int J Antimicrob Agents; 2020 Jan; 55(1):105829. PubMed ID: 31669740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of tigecycline and colistin against A. baumannii clinical bloodstream isolates during an 8-year period.
    Spiliopoulou A; Jelastopulu E; Vamvakopoulou S; Bartzavali C; Kolonitsiou F; Anastassiou ED; Christofidou M
    J Chemother; 2015 Oct; 27(5):266-70. PubMed ID: 24827985
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Yin T; Lai JJ; Huang WC; Kuo SC; Chiang TT; Yang YS;
    J Chemother; 2022 May; 34(3):166-172. PubMed ID: 34818987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.